Related Experiment Video
Updated: Jan 25, 2026

Effects of a Novel Neuromuscular Training Intervention on Jump, Sprint, and Change of Direction in Adult Female Soccer Players
Published on: June 10, 2025
How Low Do We Go (in the Post-SPRINT Era)?
1Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN.
Insights
Determining the optimal blood pressure target for chronic kidney disease (CKD) patients remains debated. This review analyzes key trial data to guide evidence-based recommendations for managing hypertension in CKD.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Hypertension is a significant cause and complication of chronic kidney disease (CKD).
- Establishing the ideal blood pressure target for CKD patients has been a long-standing clinical debate with limited guiding data.
- CKD management often involves addressing comorbid hypertension.
Purpose of the Study:
- To review existing clinical trial data to inform optimal blood pressure targets in patients with CKD.
- To analyze evidence from major trials like SPRINT, MDRD, AASK, REIN-2, and ACCORD.
- To address the clinical question regarding the lowest safe and effective blood pressure goal for CKD patients.
Main Methods:
- Systematic review of data from landmark clinical trials.
- Analysis of evidence from the Systolic Blood Pressure Intervention Trial (SPRINT).
- Inclusion of data from Modification of Diet in Renal Disease (MDRD), African American Study of Kidney Disease and Hypertension (AASK), Ramipril Efficacy in Nephropathy-2 (REIN-2), and Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials.
Main Results:
- Evidence synthesis from multiple large-scale clinical trials provides insights into blood pressure management in CKD.
- Analysis suggests potential benefits of lower blood pressure targets in specific CKD populations.
- Data interpretation aims to resolve the ongoing debate on optimal hypertension control in CKD.
Conclusions:
- The review of SPRINT, MDRD, AASK, REIN-2, and ACCORD trials offers critical evidence for setting blood pressure goals in CKD.
- Findings aim to guide clinicians in making informed decisions about hypertension management for patients with chronic kidney disease.
- Further research and consensus are needed to definitively establish the "how low should we go?" target for blood pressure in CKD.
Abstract:
Hypertension is frequently both a cause and complication of CKD. The optimal blood pressure target in CKD has been of hot debate over the decades with little data to inform the goals. Here, we review the data from the Systolic Blood Pressure Intervention Trial (SPRINT), Modification of Diet in Renal Disease (MDRD), African American Study of Kidney Disease and Hypertension (AASK), Ramipril Efficacy in Nephropathy-2 (REIN-2), and Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials to use the available evidence to better inform what blood pressure goal should be recommended in patients with CKD and to answer the question "How low should we go?".
Related Concept Videos
Post-traumatic Stress Disorder
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
Post-translational Translocation of Proteins to the RER
Targeting proteins to the ER
Hsp40 and Hsp70 chaperone molecules bind the translated proteins in the cytosol to prevent their folding. The chaperone binding helps to keep the signal...
Handwashing III: During the Procedure and Post-Procedure Steps
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Classification of Skeletal Muscle Fibers
Slow-Twitch Muscle Fibers
Slow oxidative, muscle fibers appear red due to large numbers of capillaries and high levels of...
The Colonization of Land

